5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

Inclusion Criteria: * Age: 18 to 75 years (in pediatric cases will be included in the Central Nervous System (CNS) tumor board to make decisions on therapeutic management) * Patients with radiological suspicion (contrast uptake) of high-grade glioma (Grade III-IV) * Patients with high-grade and residual glioma following surgery for gross total resection * Patients with recurrent gliomas with reoperation criteria who previously received radiotherapy and chemotherapy * Patients for whom at least one postoperative magnetic resonance imaging (MRI) was available (up to 28 days after surgery and strictly before the start of radiotherapy) * Progressing, low-grade infiltrative gliomas with one of the following criteria: * Anaplastic foci with contrast uptake in MRI * Spectroscopy study in anaplastic suspected area with high malignancy criteria * Positive choline PET-CT (positron emission tomography / computer tomography) Exclusion Criteria: * Tumors extending across midline * Basal ganglia tumor * Brainstem tumor * Multifocal gliomas * Suspected low-grade glioma without anaplastic foci * Neuraxial dissemination (ependymoma) * Karnofsky grade less than 60% * Infants or pregnant women * Acute or chronic types of porphyria * Non-acceptance of Fluorescence-Guided Surgery * Renal insufficiency confirmed by nephrological assessment * Hepatic impairment confirmed by gastroenterological assessment * Severe heart disease confirmed by cardiological assessment * Decompensated diabetes confir…